YOKENAM, Israel, Sept. 16, 2016 -- Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announces the introduction of OtoLase™, the new otology designated enhancement for the AcuPulse™ family of products. Specifically designed for enhanced precision and ease of use in middle ear surgery, the innovative OtoLase will be showcased at the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) Annual meeting 2016, being held in San Diego on September 18-21, 2016.
|
||||||||||
Photos accompanying this release are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/beee4af5-1eff-4d63-9b66-d01e88977f71 and http://www.globenewswire.com/NewsRoom/AttachmentNg/47010816-251b-4988-9289-b180a74dc97d.
The OtoLase solution, compatible with the AcuPulse DUO laser system, is a combination of reusable fiber and handpieces with different single-use tips, allowing for smooth, individualized and cost effective operation of varied pathologies in the middle ear. Based on clinical studies, otologic procedures with CO2 laser technology have shown superior outcomes compared with other modalities.1,2,3 With the ergonomic and operational design of OtoLase, surgeons are equipped with great precision and excellent visualization allowing them to remove layer-by-layer undesired tissue and enhance clinical outcomes of delicate ear procedures.
“OtoLase has been engineered for safety and ease of use. The air flow system eliminates the laser plume and facilitates visualization, and the aiming beam ensures target accuracy,” said John T. McElveen Jr., M.D. from Carolina Ear & Hearing Clinic in Raleigh, North Carolina. “The low profile and thin design allows the surgeon to reach the smallest recesses within the middle ear. This enhanced fiberoptic CO2 laser technology has been worth the wait.”
The versatile AcuPulse DUO laser system with OtoLase and the wide range of designated accessories, is an upgradable, all-inclusive solution for a range of diverse ear surgery treatments, including otosclerosis, cholesteatoma, tympanoplasty, myringotomy/tympanostomy, scar tissue dissection, acoustic neuroma and more. The laser system can be used for office and hospital-based procedures.
“With a 50-year history of redefining medical treatments and providing gold standard clinical advances, Lumenis has revolutionized the approach to micro laser surgery with its energy-based technology,” said Tzipi Ozer-Armon, CEO of Lumenis. “By striving to provide innovative tools to improve surgical performance, Lumenis continues to deliver next-generation energy-based solutions for our partners in the medical community and enhance patient care.”
AAO-HNSF conference attendees are invited to Lumenis booth #1635 to hear experts talk about their experience with the new OtoLase solution:
September 18-19 at 9:30 AM PT: Dr. Seilesh C. Babu
September 18-20 at 10 AM PT: Dr. John T. McElveen
In addition, Dr. Paul F. Castellanos will present his operating experience with the UltraPulse® DUO – the most advanced laser console in otolaryngology. His talk "The UltraPulse DUO CO2 Laser Fiber and the Difficult Airway" will take place on September 18 at 10:30 AM PT and September 19 at 1:30 PM PT.
Personal hands-on sessions on the Lumenis DUO platforms will be available all through the exhibiting hours at Lumenis booth. For more information about Lumenis, please visit: www.Lumenis.com.
About Lumenis
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL), Radio-Frequency (RF) and ultrasound. For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
References:
1. Marchese, M.R., et al., "One-shot" CO2 versus Er:YAG laser stapedotomy: is the outcome the same? Eur Arch Otorhinolaryngol, 2011. 268(3): p. 351-6.
2. Lesinski SG, Lasers for otosclerosis--which one if any and why, Lasers Surg Med. 1990;10(5):448-57.
3. Motta, G. and L. Moscillo, Functional results in stapedotomy with and without CO2 laser. ORL J Otorhinolaryngol Relat Spec, 2002. 64(5): p. 307-10.
For further information: Glenn Silver Lazar Partners Ltd. (646) 871-8495


Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 



